scholarly journals Development of Pomegranate Extract-Loaded Solid Lipid Nanoparticles: Quality by Design Approach to Screen the Variables Affecting the Quality Attributes and Characterization

ACS Omega ◽  
2020 ◽  
Vol 5 (34) ◽  
pp. 21712-21721
Author(s):  
Noha Badawi ◽  
Khalid El-Say ◽  
Dalia Attia ◽  
Mohamed El-Nabarawi ◽  
Mohey Elmazar ◽  
...  
Keyword(s):  
Solid Lipid Nanoparticles ◽  
Quality By Design ◽  
Lipid Nanoparticles ◽  
Quality Attributes ◽  
Design Approach ◽  
Solid Lipid ◽  
Quality By Design Approach

scholarly journals Application of quality-by-design approach to optimize diallyl disulfide-loaded solid lipid nanoparticles

2016 ◽  
Vol 45 (3) ◽  
pp. 474-488 ◽  
Author(s):  
Siddhartha Venkata Talluri ◽  
Gowthamarajan Kuppusamy ◽  
Veera Venkata Satyanarayana Reddy Karri ◽  
Karthik Yamjala ◽  
Ashish Wadhwani ◽  
...  
Keyword(s):  
Solid Lipid Nanoparticles ◽  
Quality By Design ◽  
Lipid Nanoparticles ◽  
Design Approach ◽  
Diallyl Disulfide ◽  
Solid Lipid ◽  
Quality By Design Approach

scholarly journals Quality by Design Approach for Development and Characterisation of Solid Lipid Nanoparticles of Quetiapine Fumarate

2020 ◽  
Vol 16 (1) ◽  
pp. 73-91 ◽  
Author(s):  
Shweta Agarwal ◽  
Rayasa S. Ramachandra Murthy ◽  
Sasidharan Leelakumari Harikumar ◽  
Rajeev Garg
Keyword(s):  
Solid Lipid Nanoparticles ◽  
Quality By Design ◽  
Lipid Nanoparticles ◽  
Lymphatic Transport ◽  
Quetiapine Fumarate ◽  
Solid Lipid ◽  
First Pass Metabolism ◽  
First Pass ◽  
Quality By Design Approach ◽  
Pass Metabolism

Background: Quetiapine fumarate, a 2nd generation anti-psychotic drug has oral bioavailability of 9% because of hepatic first pass metabolism. Reports suggest that co-administration of drugs with lipids affects their absorption pathways, enhances lymphatic transport thus bypassing hepatic first-pass metabolism resulting in enhanced bioavailability. Objective: The present work aimed at developing, and characterising potentially lymphatic absorbable Solid Lipid Nanoparticles (SLN) of quetiapine fumarate by Quality by Design approach. Method: Hot emulsification followed by ultrasonication was used as a method of preparation. Precirol ATO5, Phospholipon 90G and Poloxamer 188 were used as a lipid, stabilizer and surfactant respectively. A32 Central Composite design optimised the 2 independent variables, lipid concentration and stabilizer concentration and assessed their effect on percent Entrapment Efficiency (%EE: Y1). The lyophilized SLNs were studied for stability at 5 ±3οC and 25 ± 2οC/60 ± 5% RH for 3 months. Results: The optimised formula derived for SLN had 270mg Precirol ATO5 and 107mg of Phospholipon 90G giving %EE of 76.53%. Mean particle size was 159.8nm with polydispersity index 0.273 and zeta potential -6.6mV. In-vitro drug release followed Korsmeyer-Peppas kinetics (R2=0.917) with release exponent n=0.722 indicating non-Fickian diffusion. Transmission electron microscopy images exhibited particles to be spherical and smooth. Fourier-transform infrared spectroscopy, differential scanning calorimetry and X-ray diffraction studies ascertained drug-excipient compatibility. Stability studies suggested 5οC as appropriate temperature for storage and preserving important characteristics within acceptable limits. Conclusion: Development and optimisation by Quality by Design were justified as it yielded SLN having acceptable characteristics and potential application for intestinal lymphatic transport.

Sign in / Sign up

Export Citation Format

Share Document